logo
Is your money market fund too expensive? Why high fees may (or may not) be worth it.

Is your money market fund too expensive? Why high fees may (or may not) be worth it.

USA Today13-05-2025

Is your money market fund too expensive? Why high fees may (or may not) be worth it.
Show Caption
Hide Caption
What is a stock and how does it work?
Buying stock can be a smart way to invest and, hopefully, make more money over time.
If you're parking cash in a money market fund while waiting for recent market volatility to subside, you might be paying dearly for that safe spot.
Many money market funds still carry high expense ratios, which are management fees expressed in a percentage. The average money market fund fee is 0.38%, which is sharply higher than the 0.05% average fee on an index equity mutual fund, according to the Investment Company Institute (ICI). That means, on average, you'll pay $38 annually for every $10,000 you have invested in a money market fund compared to $5 for the index equity mutual fund.
Investors should be aware of this, so they don't fall into the trap of overpaying to hold cash.
What is a money market fund?
A money market fund is a type of mutual fund that invests in short-term, high-quality debt securities such as T-bills and certificates of deposit. Money market funds aim for high liquidity and stability.
How can investors find lower fees?
Look beyond your broker. 'Brokerage firms often limit investors to selecting from a menu of money market funds managed by the brokerage firm,' said Michael Brenner of FBB Capital Partners. 'If your broker offers you access to third-party money market funds, those may come with lower fees.'
Try an exchange-traded-fund (ETF). 'Consider using a low-cost ETF which has underlying investments that are very similar to your money market fund,' Brenner said. 'Those ETFs may carry much lower fees than a similar money market fund. Bond Index ETFs have fees that average around 0.10%.'
Are lower money market fund fees the answer?
While looking for a cheaper money market fund isn't a bad idea, some money managers say people should only be using money market funds short-term, anyway, unless they're elderly and worried about loss.
'The big rip off is if you're using them for anything more than short-term because you're not growing your money,' said Ronnie Gilliken, president and chief executive of Capital Choice of the Carolinas. Money market fund rates aren't typically enough to fulfill the "Rule of 72" over a short timeframe, he said.
The Rule of 72 is used to estimate how long it will take to double your money. Divide 72 by the interest rate (as a percentage) to get an approximate number of years it will take to double your money. The average yield for money market funds is currently around 4.14% based on data from the ICI Fact Book for 2025.
What about fees in general?
But while money market fees should be noted, investors should resist the urge to solely use fees to decide whether to invest in something or not, Gilliken said.
Instead, people should focus on net returns, he said. Otherwise, people could end up eliminating outperforming funds from the outset.
Take for example, a $10,000 investment in 1976, when Vanguard launched its first low-cost Vanguard 500 Index Fund. The Fund had an expense ratio of 0.14% when it was launched and has dropped now to 0.04%. That investment would have netted you $1,704,343 if you'd maintained it through 2023.
Compare that to the $2,455,295 you would have earned had the money been invested in the five U.S. equity-focused American Funds available at the time, American Funds said. Since that's a net return, it includes the deduction of the maximum sales charge of 5.75% for equity funds, according to American Funds.
The difference is that before buying stock of a company, analysts from the mutual fund company will visit the company, meet the chief executive and the board, get the company's financials, tour a factory or production areas, do data analysis versus the competition and if it's in a foreign country, assess political risk and legislation, Gilliken said.
'That's all included in the expense ratio,' he said. 'An index is just a thermometer of what is going on' but doesn't look at each individual company. 'Just because the company's big and in the index doesn't necessarily mean you should own it.'
Sometimes, some experts say, a slightly higher expense ratio can be worth it. Energy company Enron was in the S&P 500 but went bankrupt in the early 2000s after widespread accounting fraud, misrepresenting its financial performance and hiding billions of dollars in debt, was discovered, he noted.
Research, including from the famed Wharton business school, has shown 'active' investment managers often aren't able to pick enough winners to justify their high fees.
However, if you can find one who can, sometimes, 'we deserve our compensation,' Gilliken said.
Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@usatoday.com and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire

time3 days ago

  • Business Wire

Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced initial Phase 1 safety and efficacy data from the Phase 1/2 Agni-01 multicenter study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma (NCT06060613). These data, summarized below, will be presented in a rapid oral presentation (abstract 9517) delivered by Jason A. Chesney, M.D., Ph.D., Director and Chief Administrative Officer of UofL Health – Brown Cancer Center/Oncology Service Line at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Obsidian is also presenting a poster for abstract 9519 summarizing translational data from the Phase 1 first-in-human single-center study of OBX-115 (NCT05470283, enrollment completed) in ICI-resistant advanced melanoma. Summary of OBX-115 Safety and Efficacy Data (March 26, 2025 data cutoff): Advancing a More Patient-centric TIL Cell Therapy Regimen in Heavily Pre-treated Advanced Melanoma Patient Population Patients had disease that was predominantly ICI primary-resistant, with a median of 4 (range, 1–6) lines of prior systemic therapy, including a median of 2 (1–5) lines of prior ICI therapy (n=11). 10 patients received low-dose lymphodepletion (approximately 50% less Cyclophosphamide relative to non-engineered TIL), including 1 in the outpatient setting. Acetazolamide (ACZ) redosing following initial OBX-115 infusion to drive re-activation of OBX-115 cells was tolerable and safe enough to administer at home. OBX-115 Continues to Deliver Positively Differentiated Safety Profile Relative to Non-engineered TIL; No IL2, No Treatment-related Mortality: No dose-limiting toxicities were observed at any dose level. No Grade 4 or higher nonhematologic treatment-related adverse events (TRAEs) were reported; 5 patients experienced limited Grade 3 nonhematologic TRAEs. No confirmed events of cytokine release syndrome or infusion-related reaction higher than Grade 2; no capillary leak syndrome or immune effector cell-associated neurotoxicity syndrome were reported. No treatment-related ICU transfer, no treatment-related mortality. OBX-115 Maintains Consistent Efficacy Profile Without IL2 and With Low-dose Lymphodepletion in Anti-PD-1-resistant Advanced Melanoma; Dose Level 3 (RP2D) To Be Further Explored in Phase 2 Encouraging efficacy profile observed at the RP2D (n=6) 66.7% ORR, including 1 confirmed CR and 3 confirmed PRs (investigator-assessed RECIST 1.1 criteria) Durable clinical benefit, including 3 of 4 responses ongoing at week 24 / data cutoff (median duration of response not reached) 100% disease control rate, defined as stable disease or better for ≥12 weeks post-infusion 36.4% objective response rate (ORR) across all dose levels (n=11) Majority had reduction in tumor burden reduction: 83% at RP2D; 73% across all dose levels. Dr. Chesney commented, 'It is very encouraging to see the promising safety and efficacy profile for OBX-115, now observed in the Agni-01 multicenter study. As a highly differentiated, IL2-sparing TIL cell therapy that is compatible with low-dose lymphodepletion, OBX-115 has the potential to transform the treatment landscape and broaden the eligible population for patients with high unmet need.' 'The exciting results from OBX-115 in ICI-resistant advanced melanoma further indicate that OBX-115 has promising therapeutic potential, and that ACZ redosing is well-tolerated and has the potential to re-activate and re-expand persistent OBX-115 TIL,' commented Parameswaran Hari, M.D., Chief Development Officer of Obsidian. 'We look forward to exploring the go-forward melanoma RP2D in Phase 2, and continuing to evaluate OBX-115 in a Phase 1 cohort of patients with advanced non-small cell lung cancer, where we believe the potential impact from an IL2-sparing TIL cell therapy is clinically significant and may expand patient eligibility.' Obsidian is actively enrolling patients with advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) at multiple sites in its ongoing Phase 1/2 Agni-01 multicenter study. Additional details may be found at using identifier: NCT06060613. About OBX-115 Obsidian's lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian's proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in the phase 1/2 Agni-01 multicenter trial in patients with advanced solid tumors (NCT06060613). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. For more information, please visit and follow us on LinkedIn.

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

Business Wire

time3 days ago

  • Business Wire

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding estimated response rate of 20.13%. 1 xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving immunocheckpoint inhibitors (ICI) alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic and germline variant allele frequencies (VAFs), for a comprehensive and robust estimation of circulating tumor fraction. Tempus is presenting new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, highlighting the assay's potential to help clinicians monitor response and refine treatment strategies for patients with advanced cancers. Title: A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Location: Poster Section Developmental Therapeutics—Immunotherapy (Poster #205) Overview: Tempus xM for TRM, a liquid biopsy test, monitors treatment response by tracking ctDNA dynamics over time. Longitudinal non-molecular responders are associated with worse survival compared to molecular responders, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. 'Our comprehensive monitoring portfolio is designed to support patients throughout the cancer treatment journey,' said Halla Nimeiri, MD, Chief Development Officer at Tempus. 'We're excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies. This may impact treatment decisions, especially for patients with advanced disease, where timing is absolutely critical. With xM for TRM, clinicians can detect molecular response to ICI prior to six weeks into treatment, enabling them to stay ahead of disease progression and optimize therapeutic strategies.' About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of xM TRM and other tests, the indicated use of the xM TRM and other tests for potential clinical use, and the timing of the availability of such testing, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer
Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer

Yahoo

time6 days ago

  • Yahoo

Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer

MONMOUTH JUNCTION, N.J., May 30, 2025 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv") in collaboration with CytoDyn Inc. ("CytoDyn") presents promising four-year survival rates from a pooled clinical trial analysis of patients with metastatic triple-negative breast cancer ("mTNBC") treated with leronlimab and PD-L1 immune checkpoint inhibitors ("ICI"). Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, was tested with and without ICIs in n=28 mTNBC patients. Results indicated that leronlimab treatment correlated with increased expression of PD-L1 on circulating tumor associated cells, as measured using the LifeTracDx® blood test from Creatv. The analysis also revealed promising survival observations among patients who experienced a significant increase in PD-L1 expression and subsequently pursued treatment with an ICI. Four year follow-up results were presented at the ESMO Breast Cancer meeting on May 15, 2025 by Dr. Richard Pestell, available here. The LifeTracDx® is a universal cancer blood test that uses both circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells, macrophages that engulf tumor cells, as sensitive and accurate markers for real-time monitoring of tumor response in cancer patients. In the trials presented at ESMO, results showed that monitoring the expressions of PD-L1 before and after induction of leronlimab using the LifeTracDx® blood test identified upregulation of PD-L1 expression in 76% of patients after therapy induction. In a 4-year overall survival follow-up, 5 of the patients with upregulated PD-L1 detected by LifeTracDx® blood test and treated with the ICIs atezolizumab or pembrolizumab were alive after four years. About Creatv Bio Creatv Bio is a cancer screening and cancer diagnostics company providing testing services to patients and to pharma companies to support drug development from its laboratory in NJ. Creatv's scientists were the first to publish on CAMLs found in the blood of cancer patients. LifeTracDx® blood tests have an array of clinical applications including predicting response to a new therapy in 30 days, providing companion/complementary diagnostics such as PD-L1 using blood samples, providing information about aggressiveness of the cancer, detection of minimal residual disease, early detection of cancer recurrence, and cancer screening. For a complete listing of our journal publications and posters, please visit our website. Creatv contacts:Daniel Adams,Ron Baker Chief Scientific OfficerChief Business Officer dan@ 732-783-7132 (office)301-785-5185 (mobile) View original content to download multimedia: SOURCE Creatv MicroTech, Inc. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store